Accessibility StatementSkip Navigation Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Improvements were more pronounced in patients with only partly controlled or uncontrolled asthma: Data from long-term maintenance portion of REZOLVE-AD with 52 weeks of treatment expected in Q1 2026 from REZOLVE-AD study Top-line Phase 2b data for rezpegaldesleukin in alopecia areata ...